<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688844</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00007828</org_study_id>
    <nct_id>NCT00688844</nct_id>
  </id_info>
  <brief_title>Nutritional and Neurotransmitter Changes in PKU Subjects on BH4</brief_title>
  <acronym>BH4&amp;PKU</acronym>
  <official_title>Baseline Evaluation and Long-term Follow-up of Nutritional Status and Neurotransmitter Concentrations in Phenylketonuria Patients Initiating Treatment With Sapropterin Dihydrochloride (KuvanTM), a Tetrahydrobiopterin Analog.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atlanta Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HYPOTHESIS: The investigators hypothesize that KuvanTM therapy could influence nutritional
      and body composition parameters and neurotransmitter concentrations in pediatric and adult
      PKU subjects.

      SUMMARY: Though the investigators know that KuvanTM lowers blood Phe levels and improves
      tolerance for natural protein in at least half of the PKU (Phenylketonuria) patient
      population, investigators do not know the full effects this medicine will have on the
      patient's diet, or what impact the medicine or diet changes will have on the body composition
      or nutrient status of PKU patients. Since KuvanTM may also help the body produce
      neurotransmitters, investigators also want to find out if taking KuvanTM changes
      neurotransmitter levels in PKU patients, and if PKU patients who are benefitting from KuvanTM
      feel less stigmatized and have a better outlook on life as a result of the treatment.

      Therefore, the research study has several objectives. These are to investigate the impact
      KuvanTM therapy has on (1) body composition parameters of PKU patients: such as lean body
      mass, percent body fat, bone density, weight gain, and growth (2) dietary changes, and the
      effect of those changes, on intake of calories and essential nutrients (3) changes in blood
      biomarkers of certain nutrients (4) blood and urine neurotransmitter levels, since these
      changes could indicate improved neurological functioning, (5) and quality of life of PKU
      patients, who may feel less burdened due to the dietary freedom KuvanTM provides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND : Tetrahydrobiopterin (BH4) is a treatment option newly available to
      phenylketonuria (PKU) patients within the United States as the pharmaceutical KuvanTM. This
      small molecule functions as a cofactor in multiple enzyme systems, including the metabolism
      of phenylalanine into tyrosine by the enzyme phenylalanine hydroxylase (PAH).

      HYPOTHESIS: The investigators hypothesize that KuvanTM therapy could influence nutritional
      and body composition parameters and neurotransmitter concentrations in pediatric and adult
      PKU subjects.

      OBJECTIVES:

        1. To record nutritional biomarkers, body composition, bone density, and measures of
           nutrient intake in a phenylketonuria subject group at baseline and for one year after
           start of KuvanTM therapy.

        2. To investigate changes in monoamine neurotransmitter synthesis in a phenylketonuria
           subject group at baseline and for one year after start of KuvanTM therapy.

        3. Evaluate changes in quality of life (QOL) for PKU subjects beginning KuvanTM therapy

      METHODOLOGY: Investigators intend to enroll 60 PKU patients, ages 4 to adulthood, who are
      planning to begin BH4 treatment as prescribed by their medical provider. Patients will be
      given 4 weeks to demonstrate a response to KuvanTM as determined by a drop in plasma PHE by
      ≥15%. All patients, regardless of response to KuvanTM, will be allowed to continue in the
      study. All subjects will be followed for a full 12 months while monitoring nutrient intake,
      nutritional biomarkers, serotonin and catecholamine levels, and QOL. Two-tailed statistical
      analysis with α=0.05 will be used to compare results between responders and nonresponders, as
      well as compare follow-up values with baseline measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in BMI at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Change in Body mass index (BMI) from baseline of Kuvan study to 12 months post-baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Change in bone mineral density (BMD) from baseline of Kuvan study to 12 months post-baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Percent (%) Lean Mass at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>% lean mass was measured via dual energy x-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Percent (%) Fat Mass at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Percent fat mass measured via dual energy x-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Plasma Phenylalanine at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Full amino acid panel, including phenylalanine, analyzed in fasting plasma samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Total Dietary Protein Intake at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Total dietary protein intake assessed through 3-day food records - calculated as average protein intake (grams/day) in the 3 days recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Phenylalanine Intake at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Total dietary phenylalanine assessed through 3-day food records - calculated as average phenylalanine intake (grams/day) in the 3 days recorded</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Serotonin at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Objective: 1 year prospective cohort of PKU patients introduced to sapropterin (Kuvan)to evaluate peripheral neurotransmitter changes across time.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">58</enrollment>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>PKU subjects - baseline</arm_group_label>
    <description>Male and female subjects with PKU at baseline starting KuvanTM therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KuvanTM Therapy</intervention_name>
    <description>BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.</description>
    <arm_group_label>PKU subjects - baseline</arm_group_label>
    <other_name>BH4</other_name>
    <other_name>Kuvan</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma Blood platelets Whole blood Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Phenylketonuria (PKU) subjects ages 4 through adulthood who plan to start BH4 therapy but
        are not currently on BH4.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with PKU

          -  ability to provide informed consent (or have legal guardian who can provide informed
             consent)

          -  at least 4 years of age

          -  planning on trying BH4 treatment

        Exclusion Criteria:

          -  Pregnant

          -  unable to provide informed consent

          -  less than 4 years of age

          -  currently taking BH4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rani H Singh, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Department of Human Genetics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory Hospital, CIN/ACTSI</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Genetics Clinic</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://genetics.emory.edu/research/singh/bh4-pku-study/index.html</url>
    <description>BH4 &amp; PKU Study Opportunity</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <results_first_submitted>August 5, 2013</results_first_submitted>
  <results_first_submitted_qc>July 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2014</results_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Rani Singh</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>PKU</keyword>
  <keyword>Phenylketonuria</keyword>
  <keyword>BH4</keyword>
  <keyword>Kuvan</keyword>
  <keyword>Tetrahydrobiopterin</keyword>
  <keyword>Sapropterin Dihydrochloride</keyword>
  <keyword>Nutrition</keyword>
  <keyword>PHE</keyword>
  <keyword>Phenylalanine</keyword>
  <keyword>PAH</keyword>
  <keyword>Phenylalanine hydroxylase</keyword>
  <keyword>Neurotransmitters</keyword>
  <keyword>Serotonin</keyword>
  <keyword>Catecholamines</keyword>
  <keyword>Diet</keyword>
  <keyword>Body Fat</keyword>
  <keyword>Bone Density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Neurotransmitter Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment lasted 1 year from October 2008 - October 2009. Recruitment occurred at the Emory University Genetics Clinic, Department of Human Genetics in Decatur, GA.</recruitment_details>
      <pre_assignment_details>There were no exclusions of subjects once enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects With Phenylketonuria Starting Sapropterin Therapy</title>
          <description>Subjects with Phenylketonuria starting sapropterin therapy for the purpose of lowering blood phenylalanine levels.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Phenylketonuria Starting Sapropterin Therapy</title>
          <description>Subjects with Phenylketonuria starting sapropterin therapy for the purpose of lowering blood phenylalanine levels.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in BMI at 12 Months</title>
        <description>Change in Body mass index (BMI) from baseline of Kuvan study to 12 months post-baseline</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Data missing for 2 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Phenylketonuria Starting Sapropterin Therapy</title>
            <description>Subjects with Phenylketonuria starting sapropterin therapy for the purpose of lowering blood phenylalanine levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BMI at 12 Months</title>
          <description>Change in Body mass index (BMI) from baseline of Kuvan study to 12 months post-baseline</description>
          <population>Data missing for 2 participants</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65574" spread="8.060658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Objective was to evaluate BMI across one year in PKU patients introduced to sapropterin after baseline. Study was prospective cohort in design.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.692782</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.655574</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.060658</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bone Mineral Density (BMD) at 12 Months</title>
        <description>Change in bone mineral density (BMD) from baseline of Kuvan study to 12 months post-baseline</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Data missing for 3 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Phenylketonuria Starting Sapropterin Therapy</title>
            <description>Subjects with Phenylketonuria starting sapropterin therapy for the purpose of lowering blood phenylalanine levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bone Mineral Density (BMD) at 12 Months</title>
          <description>Change in bone mineral density (BMD) from baseline of Kuvan study to 12 months post-baseline</description>
          <population>Data missing for 3 participants</population>
          <units>grams/centimeter^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005401" spread="0.0243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Objective was to evaluate total body bone mineral density (BMD) one year via DXA in PKU patients introduced to sapropterin after baseline. Study was prospective cohort in design.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.005401</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.0243</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Percent (%) Lean Mass at 12 Months</title>
        <description>% lean mass was measured via dual energy x-ray absorptiometry (DXA)</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Data missing for 3 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Phenylketonuria Starting Sapropterin Therapy</title>
            <description>Subjects with Phenylketonuria starting sapropterin therapy for the purpose of lowering blood phenylalanine levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent (%) Lean Mass at 12 Months</title>
          <description>% lean mass was measured via dual energy x-ray absorptiometry (DXA)</description>
          <population>Data missing for 3 participants</population>
          <units>Percent Lean Mass</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.419224" spread="3.4666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Objective was to evaluate % lean mass across one year via DXA in PKU patients introduced to sapropterin after baseline. Study was prospective cohort in design.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017941</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.419224</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.4666</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Percent (%) Fat Mass at 12 Months</title>
        <description>Percent fat mass measured via dual energy x-ray absorptiometry (DXA)</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Data missing for 3 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Phenylketonuria Starting Sapropterin Therapy</title>
            <description>Subjects with Phenylketonuria starting sapropterin therapy for the purpose of lowering blood phenylalanine levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent (%) Fat Mass at 12 Months</title>
          <description>Percent fat mass measured via dual energy x-ray absorptiometry (DXA)</description>
          <population>Data missing for 3 participants</population>
          <units>Percent Fat Mass</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.208889" spread="3.519867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Objective was to evaluate % fat mass across one year via DXA in PKU patients introduced to sapropterin after baseline. Study was prospective cohort in design.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026009</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.208889</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.51967</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Plasma Phenylalanine at 12 Months</title>
        <description>Full amino acid panel, including phenylalanine, analyzed in fasting plasma samples.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Phenylketonuria Starting Sapropterin Therapy</title>
            <description>Subjects with Phenylketonuria starting sapropterin therapy for the purpose of lowering blood phenylalanine levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Phenylalanine at 12 Months</title>
          <description>Full amino acid panel, including phenylalanine, analyzed in fasting plasma samples.</description>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.5187" spread="362.9412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Objective was to evaluate plasma phenylalanine across one year in PKU patients introduced to sapropterin after baseline. Study was prospective cohort in design.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.303864</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-67.5187</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>362.9412</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Dietary Protein Intake at 12 Months</title>
        <description>Total dietary protein intake assessed through 3-day food records - calculated as average protein intake (grams/day) in the 3 days recorded</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Dietary intake not submitted by 11 participants at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Phenylketonuria Starting Sapropterin Therapy</title>
            <description>Subjects with Phenylketonuria starting sapropterin therapy for the purpose of lowering blood phenylalanine levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Dietary Protein Intake at 12 Months</title>
          <description>Total dietary protein intake assessed through 3-day food records - calculated as average protein intake (grams/day) in the 3 days recorded</description>
          <population>Dietary intake not submitted by 11 participants at 12 months.</population>
          <units>grams per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9549" spread="20.10814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Objective was to evaluate protein intake (grams per day) across one year in PKU patients introduced to sapropterin after baseline. Study was prospective cohort in design.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00088</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.9549</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>20.10814</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Phenylalanine Intake at 12 Months</title>
        <description>Total dietary phenylalanine assessed through 3-day food records - calculated as average phenylalanine intake (grams/day) in the 3 days recorded</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Dietary intake not submitted by 11 participants at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Phenylketonuria Starting Sapropterin Therapy</title>
            <description>Subjects with Phenylketonuria starting sapropterin therapy for the purpose of lowering blood phenylalanine levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Phenylalanine Intake at 12 Months</title>
          <description>Total dietary phenylalanine assessed through 3-day food records - calculated as average phenylalanine intake (grams/day) in the 3 days recorded</description>
          <population>Dietary intake not submitted by 11 participants at 12 months.</population>
          <units>grams per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.131676" spread="0.797247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Objective was to evaluate dietary phenylalanine intake across one year in PKU patients introduced to sapropterin after baseline. Study was prospective cohort in design.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3811</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.131676</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.797247</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Serotonin at 12 Months</title>
        <description>Objective: 1 year prospective cohort of PKU patients introduced to sapropterin (Kuvan)to evaluate peripheral neurotransmitter changes across time.</description>
        <time_frame>Baseline and 12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subjects With Phenylketonuria Starting Sapropterin Therapy</title>
          <description>Subjects with Phenylketonuria starting sapropterin therapy for the purpose of lowering blood phenylalanine levels.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal upset (not flu)</sub_title>
                <description>Diarrhea or acid reflux</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinus and general respiratory infections</sub_title>
                <description>Patients were asked to keep record of illnesses and other adverse events between visits. Patients were encouraged to call in adverse events that occurred between visits but were also queried at each study visit.</description>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Flu and flu-type sickness</sub_title>
                <description>Confirmed and suspected flu as reported by patients</description>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headaches or migraines reported by patients</description>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>One UTI case due to congenital kidney deformity which patient had surgically corrected a few weeks later.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Includes sore throat from strep, flu, cold, or general sore throat.</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rani H. Singh</name_or_title>
      <organization>Emory University</organization>
      <phone>404-448-8519</phone>
      <email>rsingh@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

